Min Ma, Huadan Wang, Linhong Pang, Zihong Guo, Manli Sun, Yajing Zhao, Yi Shi, Xia Wu, Junjie Song, Qiuyan Zhu, Lin Duo, Zhongjie Wang, Yu Xia, Liping He, Mingjing Tang
{"title":"云南省高血压患者持续常规用药的长期效果:一项5年随访的队列研究","authors":"Min Ma, Huadan Wang, Linhong Pang, Zihong Guo, Manli Sun, Yajing Zhao, Yi Shi, Xia Wu, Junjie Song, Qiuyan Zhu, Lin Duo, Zhongjie Wang, Yu Xia, Liping He, Mingjing Tang","doi":"10.1155/ijhy/4505824","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The relationship between different grades of compliance to antihypertensive medication and blood pressure (BP) control rate remains unclear. This study highlighted the Chinese Basic Public Health Service (BPHS) program upgraded antihypertension medication compliance to improve the blood pressure control rate contributing to the UN sustainable development goal of lowering chronic illness fatalities by one-third by 2030. <b>Methods:</b> In 2015, 1254 hypertensive patients aged ≥ 35 years were selected in the baseline survey in Yunnan Province by a multistage stratified random sampling method and followed up from 2018 to 2022. Then, they were divided into three groups by tertiles as antihypertensive medicine compliance \"poor,\" \"intermittent,\" and \"sustained\" groups. Then, the robust variance Poisson regression models were performed to estimate the association between three groups and the number of referrals. Kaplan-Meier curves calculated the cumulative risk of onset and survival probability of cardiovascular events from three medication compliance groups. <b>Results:</b> A total of 1254 hypertension patients were included in the study; 992, 1218, 1121, 1066, and 999 hypertension patients were followed up annually. From the baseline to last follow-up, systolic BP declined with the largest decrease in the sustained group (2015: 152.88 ± 21.64 mmHg vs. 2022: 134.61 ± 10.49 mmHg, <i>p</i> < 0.05) and the least decrease in the poor group (2015: 157.07 ± 15.37 mmHg vs. 2022: 140.33 ± 12.04 mmHg, <i>p</i> < 0.05). Under the management of BPHS, the BP control rate of all three groups increased significantly. Compared with the baseline, the control rate in the sustained group reached 70% in 2022 (<i>p</i> < 0.01). The number of referrals from the poor group was 11.5%, higher compared with the sustained group (IRR = 1.115 and 95% CI: 1.043-1.193). The poor group also had the highest probability of cardiovascular disease (CVD). The survival probability in the sustained group was the highest and kept at 0.950 at the end of 5 years. <b>Conclusions:</b> High-grade compliance to antihypertensive drugs significantly improves BP control rate and reduces the risk of CVD events and mortality. The decline of medication compliance grades is closely related to decreasing BP control rate and increased risk of CVD and mortality.</p>","PeriodicalId":14132,"journal":{"name":"International Journal of Hypertension","volume":"2025 ","pages":"4505824"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081157/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-Term Effects of Sustained Regular Medication in Hypertensive Patients in Yunnan, China: A Cohort Study of 5 Years' Follow-Up.\",\"authors\":\"Min Ma, Huadan Wang, Linhong Pang, Zihong Guo, Manli Sun, Yajing Zhao, Yi Shi, Xia Wu, Junjie Song, Qiuyan Zhu, Lin Duo, Zhongjie Wang, Yu Xia, Liping He, Mingjing Tang\",\"doi\":\"10.1155/ijhy/4505824\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> The relationship between different grades of compliance to antihypertensive medication and blood pressure (BP) control rate remains unclear. This study highlighted the Chinese Basic Public Health Service (BPHS) program upgraded antihypertension medication compliance to improve the blood pressure control rate contributing to the UN sustainable development goal of lowering chronic illness fatalities by one-third by 2030. <b>Methods:</b> In 2015, 1254 hypertensive patients aged ≥ 35 years were selected in the baseline survey in Yunnan Province by a multistage stratified random sampling method and followed up from 2018 to 2022. Then, they were divided into three groups by tertiles as antihypertensive medicine compliance \\\"poor,\\\" \\\"intermittent,\\\" and \\\"sustained\\\" groups. Then, the robust variance Poisson regression models were performed to estimate the association between three groups and the number of referrals. Kaplan-Meier curves calculated the cumulative risk of onset and survival probability of cardiovascular events from three medication compliance groups. <b>Results:</b> A total of 1254 hypertension patients were included in the study; 992, 1218, 1121, 1066, and 999 hypertension patients were followed up annually. From the baseline to last follow-up, systolic BP declined with the largest decrease in the sustained group (2015: 152.88 ± 21.64 mmHg vs. 2022: 134.61 ± 10.49 mmHg, <i>p</i> < 0.05) and the least decrease in the poor group (2015: 157.07 ± 15.37 mmHg vs. 2022: 140.33 ± 12.04 mmHg, <i>p</i> < 0.05). Under the management of BPHS, the BP control rate of all three groups increased significantly. Compared with the baseline, the control rate in the sustained group reached 70% in 2022 (<i>p</i> < 0.01). The number of referrals from the poor group was 11.5%, higher compared with the sustained group (IRR = 1.115 and 95% CI: 1.043-1.193). The poor group also had the highest probability of cardiovascular disease (CVD). The survival probability in the sustained group was the highest and kept at 0.950 at the end of 5 years. <b>Conclusions:</b> High-grade compliance to antihypertensive drugs significantly improves BP control rate and reduces the risk of CVD events and mortality. The decline of medication compliance grades is closely related to decreasing BP control rate and increased risk of CVD and mortality.</p>\",\"PeriodicalId\":14132,\"journal\":{\"name\":\"International Journal of Hypertension\",\"volume\":\"2025 \",\"pages\":\"4505824\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081157/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/ijhy/4505824\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/ijhy/4505824","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
摘要
背景:不同程度的降压药物依从性与血压控制率的关系尚不清楚。该研究强调,中国基本公共卫生服务(BPHS)项目提高了降压药依从性,提高了血压控制率,为联合国2030年将慢性病死亡率降低三分之一的可持续发展目标做出了贡献。方法:采用多阶段分层随机抽样方法,选取云南省2015年基线调查中年龄≥35岁的高血压患者1254例,2018 - 2022年随访。然后,他们被按性别分为抗高血压药物依从性“差”、“间歇”和“持续”三组。然后,使用稳健方差泊松回归模型来估计三组与转诊人数之间的关联。Kaplan-Meier曲线计算了三个服药依从组心血管事件发生的累积风险和生存率。结果:共纳入1254例高血压患者;每年随访992例、1218例、1121例、1066例和999例高血压患者。从基线到末次随访,收缩压下降幅度最大的是持续组(2015年:152.88±21.64 mmHg vs. 2022年:134.61±10.49 mmHg), p p p结论:降压药物的高度依从性显著提高了血压控制率,降低了CVD事件和死亡率的风险。用药依从性等级的下降与血压控制率下降、心血管疾病风险和死亡率升高密切相关。
Long-Term Effects of Sustained Regular Medication in Hypertensive Patients in Yunnan, China: A Cohort Study of 5 Years' Follow-Up.
Background: The relationship between different grades of compliance to antihypertensive medication and blood pressure (BP) control rate remains unclear. This study highlighted the Chinese Basic Public Health Service (BPHS) program upgraded antihypertension medication compliance to improve the blood pressure control rate contributing to the UN sustainable development goal of lowering chronic illness fatalities by one-third by 2030. Methods: In 2015, 1254 hypertensive patients aged ≥ 35 years were selected in the baseline survey in Yunnan Province by a multistage stratified random sampling method and followed up from 2018 to 2022. Then, they were divided into three groups by tertiles as antihypertensive medicine compliance "poor," "intermittent," and "sustained" groups. Then, the robust variance Poisson regression models were performed to estimate the association between three groups and the number of referrals. Kaplan-Meier curves calculated the cumulative risk of onset and survival probability of cardiovascular events from three medication compliance groups. Results: A total of 1254 hypertension patients were included in the study; 992, 1218, 1121, 1066, and 999 hypertension patients were followed up annually. From the baseline to last follow-up, systolic BP declined with the largest decrease in the sustained group (2015: 152.88 ± 21.64 mmHg vs. 2022: 134.61 ± 10.49 mmHg, p < 0.05) and the least decrease in the poor group (2015: 157.07 ± 15.37 mmHg vs. 2022: 140.33 ± 12.04 mmHg, p < 0.05). Under the management of BPHS, the BP control rate of all three groups increased significantly. Compared with the baseline, the control rate in the sustained group reached 70% in 2022 (p < 0.01). The number of referrals from the poor group was 11.5%, higher compared with the sustained group (IRR = 1.115 and 95% CI: 1.043-1.193). The poor group also had the highest probability of cardiovascular disease (CVD). The survival probability in the sustained group was the highest and kept at 0.950 at the end of 5 years. Conclusions: High-grade compliance to antihypertensive drugs significantly improves BP control rate and reduces the risk of CVD events and mortality. The decline of medication compliance grades is closely related to decreasing BP control rate and increased risk of CVD and mortality.
期刊介绍:
International Journal of Hypertension is a peer-reviewed, Open Access journal that provides a forum for clinicians and basic scientists interested in blood pressure regulation and pathophysiology, as well as treatment and prevention of hypertension. The journal publishes original research articles, review articles, and clinical studies on the etiology and risk factors of hypertension, with a special focus on vascular biology, epidemiology, pediatric hypertension, and hypertensive nephropathy.